Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

第3相 完了 NCT03386539

概要

The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years. Half of the participants will receive everolimus and low-dose tacrolimus and the other half will receive tacrolimus and mycophenolate mofetil. The trial will determine which treatment is better at reducing the cumulative risk of coronary artery vasculopathy, chronic kidney disease and biopsy proven-acute cellular rejection without an increase in graft loss due to all causes (e.g. infection, PTLD, antibody mediated rejection).

EFFICACY: MATE-3 Score

30 months post-randomization · Scores on a scale

SAFETY: MATE-6 Score

30 months post-randomization · Scores on a scale

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• Implantation of a Permanent Interatrial Shunt to Reduce Left Atrial Filling Pressures Foll — samir kapadia
• Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant — University of Utah
• Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure — Yale University
• PROACTIVE-HF IDE Trial Heart Failure NYHA Class III — Endotronix, Inc.
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
• Crome/Cobalt Respiration Study — Medtronic Cardiac Rhythm and Heart Failure

すべての治験